Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002, a TREM2 Activating Antibody for the Treatment of Alzheimer’s Disease, in The Journal of Experimental Medicine

Alector to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

Alector Reports 2020 First Quarter Financial Results and Business Highlights

Alector to Present at the Bank of America Securities Virtual Health Care Conference

Alector Enters into a Licensing Agreement with Innovent Biologics to Develop and Commercialize AL008 in Oncology Indications in China

Alector Reports 2019 Fourth Quarter and Full Year Financial Results and Business Highlights

Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of Directors

Alector to Present at the Cowen 40th Annual Health Care Conference

Alector Announces FDA Fast Track Designation Granted to AL101 for the Treatment of Patients with Frontotemporal Dementia

Alector Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares